Hedge fund Rubicon Founders increased its stake in Privia Health Group by 175,142 shares in Q1 2026, with the stock now representing 88.92% of the fund's portfolio. The move signals bullish sentiment, supported by Privia's strong financial performance including 26% YoY revenue growth in Q1 2026 and 59% net income growth in 2025, positioning it as a worthwhile long-term investment.

Cross Keys Capital served as exclusive financial advisor to the Neurology Group of Bergen County (NGBC) in its partnership with Privia Health. NGBC, a 50-year-old independent neurology practice in New Jersey with 25 clinicians, partnered with Privia to expand access to neurological care while maintaining its independent culture. The transaction terms were not disclosed.

Privia Health Group announced a definitive agreement to expand into New Jersey through a partnership with Neurology Group of Bergen County (NGBC), a 25-clinician neurology practice. NGBC will serve as the anchor practice for Privia Medical Group—New Jersey and is expected to be implemented on the Privia Platform by year-end 2026. The partnership aims to provide community clinicians with resources and support while maintaining NGBC's independent culture.

Privia Health Group announced Q1 2026 financial results showing strong performance with total revenue of $603.8M (up 25.8% YoY), practice collections of $914.8M (up 14.6%), and adjusted EBITDA of $36.7M (up 36.3%). The company maintained most of its full-year 2026 guidance while raising attributed lives guidance to 1.6-1.625 billion. Key operational metrics showed growth in implemented providers (5,535, up 13.6%) and attributed lives (1.606M, up 26.5%).

Privia Health Group's CFO David Mountcastle sold 13,018 shares worth approximately $283,000 over March 12-13, 2026, to cover tax obligations from vesting stock units. The sale represented 5.24% of his direct holdings. Despite a 10% stock price decline in 2026, the company reported strong Q4 FY2025 earnings, exceeding expectations with 7 cents per share, and remains optimistic about its ACO acquisition that added 1.5 million customers.

Privia Health's Accountable Care Organizations achieved $233.1 million in shared savings for 2024, a 32% increase from 2023, managing over $2.5 billion in healthcare benchmark spend across 3,280 providers serving approximately 194,700 Medicare beneficiaries.

Privia Health reported strong Q2 2025 financial performance with 23.4% revenue growth, raised full-year guidance, and expanded to 5,125 implemented providers across 15 states.

Privia Health Group, Inc. reported strong financial results for the first quarter of 2025, with increases in revenue, gross profit, operating income, and net income. The company also announced its expansion into the state of Arizona through a partnership with Integrated Medical Services, one of the largest independent multi-specialty practices in the state.

Privia Health Group, Inc. (Nasdaq: PRVA) announced that it will release its fourth quarter and full-year 2024 financial results on February 27, 2025, and host a conference call to discuss the results.

The U.S. primary care physicians market is expected to grow by $46.15 billion from 2022-2027, driven by demographic shifts, healthcare access, and the increasing prevalence of chronic diseases. Key trends include telehealth integration, patient-centered medical homes, and digital health adoption.

Privia Health to Participate in the William Blair Growth Stock Conference

Ratings for Privia Health Gr (NASDAQ:PRVA) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 3 2 0 0 Analysts have set 12-month price targets for Privia Health Gr, revealing an average target of $26.42, a high estimate of $37.00, and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.92%. Decoding Analyst Ratings: A Detailed Look The standing of Privia Health Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jailendra Singh Truist Securities Lowers Buy $24.00 $28.00 Richard Close Canaccord Genuity Lowers Buy $26.00 $37.00 Craig Jones Stifel Lowers Buy $24.00 $28.00 Daniel Grosslight Citigroup Announces Buy $25.00 - Richard Close Canaccord Genuity Lowers Buy $37.00 $41.00 Lisa Gill JP Morgan Lowers Overweight $30.00 $38.00 Andrew Mok Barclays Announces Equal-Weight $22.00 - Andrew Mok UBS Lowers Buy $29.00 $31.00 Gary Taylor TD Cowen Lowers Outperform $26.00 $30.00 Jailendra Singh Truist Securities Lowers Buy $28.00 $32.00 Elizabeth Anderson Evercore ISI Group Lowers Outperform $25.00 $26.00 Adam Ron B of A Securities Lowers Neutral $21.00 $27.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions ...Full story available on Benzinga.com